Show simple item record

dc.contributor.authorMeikle, PJ
dc.contributor.authorWong, G
dc.contributor.authorTan, R
dc.contributor.authorGiral, P
dc.contributor.authorRobillard, P
dc.contributor.authorOrsoni, A
dc.contributor.authorHounslow, N
dc.contributor.authorMagliano, DJ
dc.contributor.authorShaw, JE
dc.contributor.authorCurran, JE
dc.contributor.authorBlangero, J
dc.contributor.authorKingwell, BA
dc.contributor.authorChapman, MJ
dc.date.accessioned2020-12-21T01:52:46Z
dc.date.available2020-12-21T01:52:46Z
dc.date.issued2015-12-01
dc.identifierpii: jlr.P061143
dc.identifier.citationMeikle, P. J., Wong, G., Tan, R., Giral, P., Robillard, P., Orsoni, A., Hounslow, N., Magliano, D. J., Shaw, J. E., Curran, J. E., Blangero, J., Kingwell, B. A. & Chapman, M. J. (2015). Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. JOURNAL OF LIPID RESEARCH, 56 (12), pp.2381-2392. https://doi.org/10.1194/jlr.P061143.
dc.identifier.issn0022-2275
dc.identifier.urihttp://hdl.handle.net/11343/256697
dc.description.abstractThe impact of statin treatment on the abnormal plasma lipidome of mixed dyslipidemic patients with metabolic syndrome (MetS), a group at increased risk of developing diabetes, was evaluated. Insulin-resistant hypertriglyceridemic hypertensive obese males (n = 12) displaying MetS were treated with pitavastatin (4 mg/day) for 180 days; healthy normolipidemic age-matched nonobese males (n = 12) acted as controls. Statin treatment substantially normalized triglyceride (-41%), remnant cholesterol (-55%), and LDL-cholesterol (-39%), with minor effect on HDL-cholesterol (+4%). Lipidomic analysis, normalized to nonHDL-cholesterol in order to probe statin-induced differences in molecular composition independently of reduction in plasma cholesterol, revealed increment in 132 of 138 lipid species that were subnormal at baseline and significantly shifted toward the control group on statin treatment. Increment in alkyl- and alkenylphospholipids (plasmalogens) was prominent, and consistent with significant statin-induced increase in plasma polyunsaturated fatty acid levels. Comparison of the statin-mediated lipidomic changes in MetS with the abnormal plasma lipidomic profile characteristic of prediabetes and T2D in the Australian Diabetes, Obesity, and Lifestyle Study and San Antonio Family Heart Study cohorts by hypergeometric analysis revealed a significant shift toward the lipid profile of controls, indicative of a marked trend toward a normolipidemic phenotype. Pitavastatin attenuated the abnormal plasma lipidome of MetS patients typical of prediabetes and T2D.
dc.languageEnglish
dc.publisherAMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
dc.titleStatin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
dc.typeJournal Article
dc.identifier.doi10.1194/jlr.P061143
melbourne.affiliation.departmentBio21
melbourne.affiliation.departmentPhysiology
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.source.titleJournal of Lipid Research
melbourne.source.volume56
melbourne.source.issue12
melbourne.source.pages2381-2392
dc.rights.licenseCC BY
melbourne.elementsid1105187
melbourne.contributor.authorMeikle, Peter
melbourne.contributor.authorKingwell, Bronwyn
melbourne.contributor.authorMagliano, Dianna
dc.identifier.eissn1539-7262
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record